

Radiodermatitis - Drugs in Development, 2021

<https://marketpublishers.com/r/R9D5472CFD9DEN.html>

Date: November 2021

Pages: 73

Price: US\$ 2,000.00 (Single User License)

ID: R9D5472CFD9DEN

Abstracts

Radiodermatitis - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Drugs In Development, 2021, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).

The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Radiodermatitis - Overview
- Radiodermatitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Radiodermatitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Radiodermatitis - Companies Involved in Therapeutics Development
- Allander Biotechnologies LLC
- Amryt Pharma Plc
- BioCurity Pharmaceuticals Inc
- Clevexel Pharma SA
- Enveric Biosciences Inc
- Foresee Pharmaceuticals Co Ltd
- Lutris Pharma
- Matrix Biomed Inc
- Neuropathix Inc
- Noveome Biotherapeutics Inc
- Perpetuum BV
- Regeneus Ltd
- RepoCeuticals ApS
- Sunny Pharmtech Inc
- VasoDynamics Ltd
- Radiodermatitis - Drug Profiles
- Biologic for Radiodermatitis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- birch triterpenes - Drug Profile
- Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0095 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And

Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUT-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NG-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NG-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCSMD-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sygenus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tempol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZM-241385 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiodermatitis - Dormant Projects

Radiodermatitis - Discontinued Products

Radiodermatitis - Product Development Milestones

Featured News & Press Releases

Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders

Sep 24, 2020: Allander Biotechnologies announces NIH Small Business Innovation Research phase II funding

Jul 29, 2020: Jay Pharma to file IND applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination therapy in glioblastoma

Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1,

3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Radiodermatitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Radiodermatitis - Pipeline by Allander Biotechnologies LLC, 2021
Radiodermatitis - Pipeline by Amryt Pharma Plc, 2021
Radiodermatitis - Pipeline by BioCurity Pharmaceuticals Inc, 2021
Radiodermatitis - Pipeline by Clevexel Pharma SA, 2021
Radiodermatitis - Pipeline by Enveric Biosciences Inc, 2021
Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, 2021
Radiodermatitis - Pipeline by Lutris Pharma, 2021
Radiodermatitis - Pipeline by Matrix Biomed Inc, 2021
Radiodermatitis - Pipeline by Neuropathix Inc, 2021
Radiodermatitis - Pipeline by Noveome Biotherapeutics Inc, 2021
Radiodermatitis - Pipeline by Perpetuum BV, 2021
Radiodermatitis - Pipeline by Regeneus Ltd, 2021
Radiodermatitis - Pipeline by RepoCeuticals ApS, 2021
Radiodermatitis - Pipeline by Sunny Pharmtech Inc, 2021
Radiodermatitis - Pipeline by VasoDynamics Ltd, 2021
Radiodermatitis - Dormant Projects, 2021
Radiodermatitis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Radiodermatitis, 2021
- Number of Products under Development by Companies, 2021
- Number of Products by Targets, 2021
- Number of Products by Stage and Targets, 2021
- Number of Products by Mechanism of Actions, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Top 10 Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Radiodermatitis - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/R9D5472CFD9DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9D5472CFD9DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970